Oncology and Hematology: Archives

SUMMARY AND COMMENT

A Novel Erythropoietin Receptor Agonist for Red Cell Aplasia

• November 4, 2009
• David Green, MD, PhD

Hemoglobin levels improved after treatment in patients who had antierythropoietin antibodies.

• Reviewing:
• Macdougall IC et al., N Engl J Med 2009 Nov 5; 361:1848

SUMMARY AND COMMENT

MicroRNA Expression in Hepatocellular Cancer

• November 3, 2009
• David H. Ilson, MD, PhD

Low expression of miR-26 seemed to affect survival and predict response to interferon.

• Reviewing:
• Ji J et al., N Engl J Med 2009 Oct 8; 361:1437

SUMMARY AND COMMENT

Omitting Radiation for Patients with DCIS

• November 3, 2009
• Henry Mark Kuerer, MD, PhD, FACS

Local tumor excision alone yielded acceptably low rates of local recurrence in patients with low- and intermediate-grade DCIS.

• Reviewing:
• Hughes LL et al., J Clin Oncol 2009 Oct 13

SUMMARY AND COMMENT

Preventing Oral Mucositis in Cancer Treatment

• October 27, 2009
• Barbara A. Murphy, MD

Recombinant human intestinal trefoil factor produced encouraging results.

• Reviewing:
• Peterson DE et al., J Clin Oncol 2009 Sep 10; 27:4333

SUMMARY AND COMMENT

Sorafenib for Metastatic Renal Cell Cancer

• October 27, 2009
• Robert Dreicer, MD, MS, FACP

Sorafenib had limited activity in patients with sunitinib-refractory disease.

• Reviewing:
• Di Lorenzo G et al., J Clin Oncol 2009 Sep 20; 27:4469

SUMMARY AND COMMENT

CYP2D6 Polymorphisms and Response to Tamoxifen

• October 27, 2009
• Virginia Kaklamani, MD, DSc

Breast cancer patients with genotypes corresponding to normal CYP2D6 enzyme activity achieved better outcomes than those with diminished or no activity.

• Reviewing:
• Schroth W et al., JAMA 2009 Oct 7; 302:1429

SUMMARY AND COMMENT

Daunorubicin for Younger Adults with Acute Myeloid Leukemia

• October 20, 2009
• Michael E. Williams, MD

High-dose daunorubicin improved complete response rates in patients aged 60 and younger and survival in those younger than 50.

• Reviewing:
• Fernandez HF et al., N Engl J Med 2009 Sep 24; 361:1249

SUMMARY AND COMMENT

Daunorubicin for Older Adults with Acute Myeloid Leukemia

• October 20, 2009
• Michael E. Williams, MD

High-dose daunorubicin improved complete response rates in patients aged 60 and older but did not improve survival overall.

• Reviewing:
• Löwenberg B et al., N Engl J Med 2009 Sep 24; 361:1235 Dombret H and Gardin C., N Engl J Med 2009 Sep 24; 361:1301

SUMMARY AND COMMENT

Erythropoietin for Myelodysplastic Syndromes

• October 20, 2009
• David Green, MD, PhD

Correction of anemia was safe and improved quality of life.

• Reviewing:
• Greenberg PL et al., Blood 2009 Sep 17; 114:2393

SUMMARY AND COMMENT

Androgens, Telomerase, and Aplastic Anemia

• October 20, 2009
• David Green, MD, PhD

Investigators uncovered a potential mechanism for androgen efficacy in aplastic anemia.

• Reviewing:
• Calado RT et al., Blood 2009 Sep 10; 114:2236